InspireMD Inc
Change company Symbol lookup
Select an option...
NSPR InspireMD Inc
GLDD Great Lakes Dredge & Dock Corp
CLVT Clarivate PLC
WTER Alkaline Water Company Inc
DSL DoubleLine Income Solutions Fund
GCO Genesco Inc
MPAA Motorcar Parts of America Inc
FMCKL Federal Home Loan Mortgage Corp
FNHC Fednat Holding Co
PIRS Pieris Pharmaceuticals Inc
Go

Health Care : Health Care Equipment & Supplies | Small Cap Value
Based in Israel
Company profile

InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.

Price
Delayed
$1.93
Day's Change
0.01 (0.52%)
Bid
--
Ask
--
B/A Size
--
Day's High
1.97
Day's Low
1.92
Volume
(Light)

Today's volume of 9,335 shares is on pace to be much lighter than NSPR's 10-day average volume of 25,099 shares.

9,335

Company Profile

InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
3.44x
Price/Book (MRQ)
0.54x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend No Regular Dividend is paid
 

Short Interest

July 2022
Current Month
31.4K
Previous Month
37.2K
Percent of Float
0.41%
Days to Cover
2.6611 Days

Share Information

NSPR is in a share class of common stock
Float
7.6M
Shares Outstanding
8.3M
Institutions Holding Shares
16
1.67%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Paul S. Stuka
  • Marvin L. SlosmanPres.
  • Craig ShoreCFO
  • Kathryn Arnold
  • Michael Berman

Address

  • 4 Menorat Hamaor St.
  • Tel Aviv-Yafo, 6744832
  • Israel
  • Phone: 8574536553
  • Fax: 3026555049

Insider Trading

No insider trading activity.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.